New Data Cast Doubt On Effectiveness, Safety Of Weight-Loss Medication.

“Science Now” that the cardiovascular safety of the weight-loss drug Contrave (naltrexone/bupropion) “remains uncertain,” according to the halfway point results of the LIGHT trial published in JAMA. The researchers also concluded that claims that the drug significantly reduces the risk of heart attack and stroke are also premature. Although the Food and Drug Administration’s approval was based upon an agreement with the drugmaker to continue the LIGHT trial to study the drug’s safety and effectiveness, the trial “was abandoned after the makers of Contrave flouted the terms of their agreement with the FDA and the researchers conducting the clinical trial and made the preliminary safety findings public.” http://www.latimes.com/science/sciencenow/la-sci-sn-heart-attack-stroke-diet-drug-contrave-20160308-story.html